# Supplementary Figure.1 ALBI score over time in patients with ALBI grade 1 treated by Lenvatinib (n=19) or TACE (n=37) (propensity score matched results)

	Baseline	1 month	2 month	3 month	End Of Treatment
Lenvatinib	-2.87	-2.60	-2.57	-2.67	-2.74
TACE	-2.93	-2.42	-2.38	-2.37	-2.23

* p<0.05 (Lenvatinib vs. TACE)
** p<0.01 (Lenvatinib vs. TACE)
# p<0.01 (vs. TACE at baseline)

Supplementary Figure.2 Progression Free Survival (ALBI grade 1; propensity score matched)

Median PFS (month: 95% CI)
— Lenvatinib 16.0 (10.2 − NR)
— TACE 3.0 (2.1 − 4.4)
HR 0.16 (0.07-0.34), p<0.001

Number of at risk

	0	3	6	9	12	15
Lenvatinib	19	19	19	15	8	5
TACE	37	18	7	6	5	2

Supplementary Figure.3 Overall Survival (ALBI grade 1; propensity score matched)

Supplementary Table 1. Objective Response Rate (propensity score matched) (ALBI grade 1; propensity score matched)

	Lenvatinib n = 19 (%)	TACE n = 37 (%)	P-value Odds ratio (95%CI)
ORR	14 (73.7%)	14 (37.8%)	P<0.05 4.47 (1.19 – 19.51)
CBR (CR + PR + SD ≥24w)	19 (100.0%)	16 (36.7%)	
DCR	19 (100.0%)	22 (55.0%)	
CR	1	4	
PR	13	10	
SD	5	8	
Durable stable disease (SD ≥24w)	5	2	
PD	0	13	
NE	0	2	

ORR; objective response rate, CBR; clinical benefit rate, DCR; disease control rate, CR; complete response rate, PR; partial response, SD; stable disease, PD; progressive disease, NE; not evaluable